Table 2.

Clinical potential of exosomal lncRNAs in NSCLC.

Exosomal lncRNAs	Sample	Group	Expression	Role	References
GAS5	Serum	NSCLC (n = 64) vs. healthy controls (n = 40)	Decreased	Diagnostic biomarker	131
DLX6-AS1	Serum	NSCLC (n = 72) vs. healthy controls (n = 64)	Increased	Diagnostic biomarker	132
SOX2-OT	Plasma	LSCC (n = 75) vs. negative controls (n = 79)	Increased	Diagnostic biomarker and therapeutic target	121, 136
LINC00917	Serum	NSCLC (n = 179) vs. healthy controls (n = 104)	Increased	Diagnostic biomarker	133
TBILA and AGAP2-AS1	Serum	NSCLC (n = 150) vs. healthy controls (n = 150)	Increased	Diagnostic biomarker	134
SLC9A3-AS1 and PCAT6	Peripheral blood	Lung cancer (n = 32) vs. healthy controls (n = 30)	Increased	Diagnostic biomarker	135
HOTAIR	Serum	NSCLC (n = 32) vs. healthy controls (n = 20)	Increased	Diagnostic biomarker	83
SNHG15	Serum	NSCLC (n = 118) vs. benign pulmonary lesions (n = 40) vs. healthy controls (n = 80)	Increased	Diagnostic and prognostic biomarker	137
LINC01125	Serum	NSCLC (n = 6) vs. pneumonia controls (n = 5)	Increased	Diagnostic and prognostic biomarker	138
		NSCLC (n = 63) vs. tuberculosis (n = 59)
		NSCLC (n = 150) vs. disease-free controls (n = 187)
		NSCLC (n = 62) vs. disease-free controls (n = 95)
RP5-977B1	Serum	NSCLC (n = 105) vs. healthy controls (n = 51)	Increased	Diagnostic and prognostic biomarker	47
HAGLR	Plasma	NSCLC (n = 40) vs. healthy controls (n = 8)	Decreased	Prognostic	139
lnc-MMP2-2	Culture medium	TGF-β-treated vs. non-TGF-β-treated A549 cells	Increased	Therapeutic target	91, 96
H19	Culture medium	Gefitinib‑resistant cells vs. sensitive parent cells	Increased	Therapeutic target	111
LINC00662	Plasma	/	Increased	Therapeutic target	85
UCA1	Culture medium	Gefitinib resistant vs. Gefitinib-sensitive	Increased	Therapeutic target	112
RP11‑838N2.4	Serum, culture medium	Erlotinib-resistant cells vs. normal NSCLC cells	Increased	Therapeutic target	113
lnc-MZT2A-5:1	Culture medium	Osimertinib-resistant cells vs. normal NSCLC cells	Increased	Therapeutic target	123